Aaron Berger, MD, discusses patient selection for ARPI treatment holidays, monitoring during interruptions, and the role of testosterone recovery in interpreting PSA kinetics.
|Videos|March 25, 2021
UTI incidence is low among infants who have spina bifida
Author(s)Urology Times staff
“For now, the UMPIRE [study] protocol will continue to withhold prophylaxis in the newborn population,” says investigator M. Chad Wallis, MD, FACS.
Advertisement
In this video, M. Chad Wallis, MD, FACS, discusses the recent Journal of Urology paper, “Incidence of Urinary Tract Infections in Newborns with Spina Bifida: Is Antibiotic Prophylaxis Necessary?, for which he served as a study author. Wallis is a clinical associate professor of surgery in the division of urology at the University of Utah in Salt Lake City.
Advertisement
Related to this article
Paras H. Shah, MD, recaps data on emerging agents in high-risk NMIBC from the 2026 AUA North Central Section Meeting.
Tamim Niazi, MDCM, reviews DASL-HiCaP findings showing improved metastasis-free survival with darolutamide added to ADT and radiation therapy.
Chad Ritch, MD, discusses differences between PSMA-PET imaging agents and the need for further evidence to guide clinical decision-making.
Chad Ritch, MD, discusses how PSMA-PET informs patient management across different stages of the prostate cancer journey.
Alicia K. Morgans, MD, MPH, reviews promising prostate cancer findings from ESMO 2026,
Alberto Briganti, MD, PhD, discusses results from the PROTEUS substudy, evaluating perioperative apalutamide plus ADT vs surgery alone in high-risk localized or locally advanced prostate cancer.
Andrea Necchi, MD, discusses how results from the CA017-078 trials compares with other perioperative immunotherapy trials in muscle-invasive bladder cancer.
Advertisement
Advertisement
Trending on Urology Times
1
Tamim Niazi, MDCM, reviews darolutamide data from DASL-HiCaP
2
2026 AUA North Central Section Meeting: Updates in high-risk NMIBC
3
FDA updates in urology: October 2026
4
UGN-101 shows durable responses in low-grade upper tract urothelial carcinoma
5